



### CLAIMS

1. A method for targeting a pharmaceutical agent to a noncentral nervous system tissue to treat a noncentral nervous system condition comprising:  
administering to a subject in need of such treatment a covalent conjugate of *cis*-docosahexanoic acid and a pharmaceutical agent effective for treating said condition.
2. The method of claim 1, wherein the tissue is breast tissue and wherein the subject has a condition calling for treatment of breast tissue with the pharmaceutical agent.
3. The method of claim 1, wherein the tissue is gastrointestinal tissue and wherein the subject has a condition calling for treatment of gastrointestinal tissue with the pharmaceutical agent.
4. The method of claim 1, wherein the tissue is ovarian tissue and wherein the subject has a condition calling for treatment of ovarian tissue with the pharmaceutical agent.
5. The method of claim 1, wherein the pharmaceutical agent is a noncentral nervous system active agent that is nonactive within the central nervous system.
6. The method of claim 1, wherein the drug is an anti-cancer agent.
7. The method of claim 6, wherein the drug is Taxol.
8. The method of claim 7, wherein the conjugate is




9. The method of claim 7, wherein the conjugate is




10. The method of claim 6, wherein the drug is Taxotere.


11. The method of claim 10, wherein the conjugate is




12. The method of claim 10, wherein the conjugate is



13. The method of claim 10, wherein the conjugate is



14. The method of claim 10, wherein the conjugate is



15. The method of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, wherein the condition is breast cancer.

16. The method of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, wherein the condition is colon cancer.

17. The method of claim 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, wherein the condition is ovarian cancer.

18. A pharmaceutical preparation comprising:

a covalent conjugate of *cis*-docosahexanoic acid and a noncentral nervous system active agent, and

a pharmaceutically acceptable carrier.

19. The pharmaceutical preparation as claimed in claim 19, wherein the noncentral nervous system active agent is active on a tissue selected from the group consisting of:

Blood and Blood Forming tissue; Cardiovascular system tissue; Digestive and excretory system tissue; Endocrine system tissue; Musclar system tissue; Reproductive System tissue; Respiratory system tissue; Skeletal system tissue; and Fiber and integumentary system tissue.